A Cancer-Specific Anti-Podocalyxin Monoclonal Antibody-Drug Conjugate Exerted Antitumor Activity in a Pancreatic Cancer Xenograft Model

Podocalyxin (PODXL) is a potential diagnostic biomarker and therapeutic target in various tumors. Development of anti-PODXL mAbs has been limited by concerns about potential reactivity with normal tissues. To minimize on-target, off-tumor toxicities and adverse effects, we developed cancer-specific mAbs (CasMabs) against PODXL and demonstrated antitumor efficacy in human tumor xenograft models. In this study, we evaluated humPcMab-60-DXd, an anti-PODXL CasMab conjugated with DXd, a derivative of the topoisomerase I inhibitor exatecan. humPcMab-60-DXd retained cancer-specific reactivity with the pancreatic ductal adenocarcinoma MIA PaCa-2 cell line. Furthermore, humPcMab-60 was internalized into MIA PaCa-2 and inhibited cell proliferation in vitro. In the MIA PaCa-2 xenograft model, humPcMab-60-DXd showed superior antitumor efficacy compared with humPcMab-60. Moreover, humPcMab-60-DXd exhibited dose-dependent antitumor activity without reducing mice body weight. Histological analyses revealed the collapse of the intratumoral structure and a reduction in PODXL expression in the humPcMab-60-DXd-treated xenograft. These results provide the first observation of antitumor efficacy for an anti-PODXL CasMab–drug conjugate, which could facilitate the clinical development of CasMabs for tumor therapy.

Authors

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-17
DOI
https://doi.org/10.3390/ijms272210317
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A Cancer-Specific Anti-Podocalyxin Monoclonal Antibody-Drug Conjugate Exerted Antitumor Activity in a Pancreatic Cancer Xenograft Model

Takuro Nakamura, Hiroyuki Suzuki, Tomokazu Ohishi, Mika Kato Kaneko et al.
1 links
International Journal of Molecular Sciences
Monoclonal and Polyclonal Antibodies Research
article

A Cancer-Specific Anti-Podocalyxin Monoclonal Antibody-Drug Conjugate Exerted Antitumor Activity in a Pancreatic Cancer Xenograft Model

Takuro Nakamura, Hiroyuki Suzuki, Tomokazu Ohishi, Mika Kato Kaneko, Yukinari Kato
article en

Abstract

Podocalyxin (PODXL) is a potential diagnostic biomarker and therapeutic target in various tumors. Development of anti-PODXL mAbs has been limited by concerns about potential reactivity with normal tissues. To minimize on-target, off-tumor toxicities and adverse effects, we developed cancer-specific mAbs (CasMabs) against PODXL and demonstrated antitumor efficacy in human tumor xenograft models. In this study, we evaluated humPcMab-60-DXd, an anti-PODXL CasMab conjugated with DXd, a derivative of the topoisomerase I inhibitor exatecan. humPcMab-60-DXd retained cancer-specific reactivity with the pancreatic ductal adenocarcinoma MIA PaCa-2 cell line. Furthermore, humPcMab-60 was internalized into MIA PaCa-2 and inhibited cell proliferation in vitro. In the MIA PaCa-2 xenograft model, humPcMab-60-DXd showed superior antitumor efficacy compared with humPcMab-60. Moreover, humPcMab-60-DXd exhibited dose-dependent antitumor activity without reducing mice body weight. Histological analyses revealed the collapse of the intratumoral structure and a reduction in PODXL expression in the humPcMab-60-DXd-treated xenograft. These results provide the first observation of antitumor efficacy for an anti-PODXL CasMab–drug conjugate, which could facilitate the clinical development of CasMabs for tumor therapy.

International Journal of Molecular SciencesVol. 27(22)
Japan Agency for Medical Research and Development
Good health and well-being
Monoclonal and Polyclonal Antibodies Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon